Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology | Hematology

Lymphomas

Alabama

Birmingham : Birmingham Hematology and Oncology Associates, LLC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Huntsville : Clearview Cancer Institute

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Mobile : Southern Cancer Center, PC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Muscle Shoals : Northwest Alabama Cancer Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Arizona

Peoria : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Arkansas

Jonesboro : Clopton Clinic

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

California

Anaheim : Pacific Cancer Medical Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Burbank : Providence Saint Joseph Medical Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Duarte : City of Hope

A Phase I/II Study of VELCADE in Combination with Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma

Duarte : City of Hope

COG AHOD0031: A Phase III Group-Wide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease

Duarte : City of Hope

Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation, AnorMED Protocol, AMD3100-CUP001

Duarte : City of Hope

Obtaining Leukapheresed Peripheral Blood Mononuclear Cells from Healthy Volunteer Donors for Use in T Cell Program

Duarte : City of Hope

Prospective Chart Review for Data Inclusion into Sentinel Node Working Group

Fountain Valley : St. Joseph Mercy Hospital

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Fresno : Cancer Care Associates of Fresno Medical Group, Inc.

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Gilroy : Ronald H. Yanagihara, MD

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Greenbrae : California Cancer Care, Inc.

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

La Jolla : Scripps Cancer Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

La Jolla : Moores UCSD Cancer Center

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

La Verne : Wilshire Oncology Medical Group, Inc.

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Loma Linda : Loma Linda U Cancer Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Los Angeles : East Valley Hematology & Oncology Medical Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Los Angeles : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Orange : Medical Oncology Care Associates

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Pleasant Hill : Bay Area Cancer Research Group

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Rancho Mirage : Desert Hematology Oncology Medical Group

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Salinas : Los Palos Oncology and Hematology

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

San Diego : Scripps Clinic

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Colorado

Denver : Rocky Mountain Cancer Centers, LLP

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Denver : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Connecticut

Fairfield : Medical Specialists of Fairfield

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Southington : Cancer Center of Central Connecticut

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Stamford : Hematology Oncology, PC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Florida

Gainesville : Gainesville Hematology Oncology Associates

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Hialeah : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Jacksonville : Integrated Community Oncology Network

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

New Port Richey : Florida Cancer Institute - New Hope

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Ocala : Ocala Cancer Institute

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Pensacola : Hematology Oncology Associates, P.A. dba The Hope Medical Group

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Rockledge : Hematology Oncology Associates of Central Brevard

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Georgia

Augusta : Augusta Oncology Associates, PC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Marietta : Northwest Georgia Oncology Centers, PC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Marietta : Northwest Georgia Oncology Centers PC

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Roswell : Atlanta Cancer Care

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Illinois

Centralia : Southern Illinois Hematology Oncology

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Chicago : Rush University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Chicago : University of Chicago

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Chicago : Northwestern University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Galesburg : Medical and Surgical Specialists, LLC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Harvey : Ingalls Memorial Hospital

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Hines : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Joliet : Joliet Oncology Hematology Associates, Ltd

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Skokie : Northshore Cancer Research Association

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Skokie : Clintell, Inc.

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Urbana : Carle Clinic Association

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Indiana

Beech Grove : St. Francis Hospital and Health Centers

Safety and Efficacy of RAD001 in Patients With Velcade® Refractory Mantle Cell Lymphoma (PILLAR-1)

New Albany : Cancer Care Center Inc

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Newburgh : Oncology Hematology Associates of Southwest Indiana

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Iowa

Ames : McFarland Clinic, PC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Iowa City : University of Iowa Hospital

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Sioux City : Siouxland Hematology Oncology Associates

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Kansas

Hutchinson : Hutchinson Clinic

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Wichita : Cancer Center of Kansas

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Kentucky

Hazard : Kentucky Cancer Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Louisville : Kentuckiana Cancer Institute PLLC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Louisiana

Metairie : Hematology and Oncology Specialists, LLC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Maine

Scarborough : Maine Center for Cancer Medicine

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Maryland

Annapolis : Annapolis Oncology Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Baltimore : Sinai Hospital of Baltimore, Alvin and Lois Lapidus Cancer Institute

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Baltimore : Harry and Jeanette Weinberg Cancer Institute at Franklin Square

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Columbia : Maryland Oncology Hematology, P.A.

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Massachusetts

Boston : Dana-Farber Cancer Institute

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Michigan

Ann Arbor : University of Michigan

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Ann Arbor : St. Joseph Mercy Hospital

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Detroit : Barbara Ann Karmanos Cancer Institute

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Kalamazoo : Kalamazoo Hematology and Oncology

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Southfield : Southfield Oncology Institute, Inc.

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Woodhaven : Osteopathic Medical Oncology and Hematology, PC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Missouri

Chesterfield : Saint Louis Cancer Care, LLP

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Kansas City : Heartland Hematology Oncology Associates, Inc.

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Saint Louis : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

St. Joseph : St. Joseph Oncology Inc.

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Montana

Missoula : Montana Cancer Specialists

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Nebraska

Lincoln : Nebraska Hematology/Oncology

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

North Platte : Great Plains Regional Medical Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

New Hampshire

Lebanon : Dartmouth Hitchcock Medical Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Lebanon : Dartmouth Hitchcock Medical Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Portsmouth : Portsmouth Regional Hospital

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

New Jersey

Belleville : Essex Oncology of North Jersey

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Denville : Oncology and Hematology Specialists, P.A.

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Morristown : Hematology Oncology Associates of Northern New Jersey, PA, Carol G. Simon Cancer Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Newark : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New Mexico

Albuquerque : New Mexico Oncology Hematology Consultants, Ltd.

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

New York

Buffalo : Zale P. Bernstein, MD, PC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

East Syracuse : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Fresh Meadows : Queens Medical Associates, PC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Huntington Station : Huntington Medical Group

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

New York : Mount Sinai Medical Center

A Pilot Study of Arsenic Trioxide in the Treatment of Relapsed and Refractory Indolent Lymphomas

New York : Columbia University

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Nyack : Hematology Oncology Associates of Rockland

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Rochester : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Valhalla : New York Medical College

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

North Carolina

Asheville : Cancer Care of Western North Carolina, PA

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Burlington : Alamance Oncology Hematology Associates

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Chapel Hill : University of North Carolina

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Durham : Duke University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Hickory : Carolina Oncology Specialists, PA

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Huntersville : Carolina BioOncology Institute

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Winston Salem : Wake Forest University Health Sciences

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Ohio

Canton : Gabrail Cancer Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Cleveland : Metro Health Medical Center, Cancer Care Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Cleveland : Case Western Reserve University Ireland Cancer Center

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Columbus : Hematology Oncology Consultants, Inc.

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Columbus : The Ohio State University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Medina : Mukesh C. Bhatt, MD, Inc.

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Middletown : Signal Point Clinical Research Center, LLC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Oregon

Beaverton : Pacific Oncology, PC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Portland : Oregon Health & Science University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Pennsylvania

Danville : Geisinger Medical Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Lemoyne : Central Pennsylvania Hematology Medical Oncology Associates

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Philadelphia : Temple University

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Philadelphia : Temple University

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Pittsburgh : The University of Pittsburgh Medical Center (UPMC)

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Pittsburgh : Western Pennsylvania Cancer Institute

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Pittsburgh : Allegheny General Hospital

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma[DISABLED]

Willow Grove : Abington Hematology Oncology Associates, Inc.

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Rhode Island

Providence : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

South Carolina

Charleston : Charleston Hematology Oncology Associates, PA

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Greenville : Cancer Centers of the Carolinas

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Hilton Head Island : South Carolina Cancer Specialists

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Sumter : Santee Hematology Oncology

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

South Dakota

Sioux Falls : Avera Cancer Institute

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Tennessee

Bristol : Blue Ridge Medical Specialists, PC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Collierville : Family Cancer Center, PLLC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Johnson City : McLeod Cancer and Blood Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Knoxville : Tennessee Cancer Specialists

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Texas

Corpus Christi : Coastal Bend Cancer Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Dallas : Texas Hematology Oncology Center, PA

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Duncanville : Dallas Oncology Consultants, PA

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Houston : University of Texas

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Houston : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Mantle Zone Lymphoma

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Primary Central Nervous System Lymphoma

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Primary Lymphoma Of The Gastrointestinal Tract

Richardson : HOPE Oncology

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

San Antonio : Cancer Care Centers of South Texas

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Utah

Ogden : Northern Utah Associates

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Ogden : Northern Utah Associates

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Virginia

Salem : Blue Ridge Cancer Care

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Washington

Kennewick : Columbia Basin Hematology and Oncology

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Seattle : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Tacoma : Northwest Medical Specialists, PLLC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Walla Walla : Saint Mary Medical Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

West Virginia

Huntington : Marshall University

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Wisconsin

Green Bay : Aurora BayCare Medical Center

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Marshfield : Marshfield Clinic

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Wauwatosa : Oncology Alliance, SC

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Australia

South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Denmark

Hillerød : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

København : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Roskilde : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

France

Creteil : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Le Mans : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Lille : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Montpellier : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Nantes : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Paris : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Pierre Benite : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Rennes : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Rouen : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Toulouse : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Tours : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Vandoeuvre-Les-Nancy : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Germany

Köln : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Israel

Haifa : Rambam Healthcare Campus

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Jerusalem : Hadassah Medical Organization

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Tel-Hashomer : Chaim Sheba Medical Center

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Norway

Bergen : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Oslo : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Stavanger : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Tromsø : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Trondheim : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Puerto Rico

Heto Ray : Auxilio Cancer Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Spain

Barcelona : Research Site:

A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Sweden

Eskilstuna : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Falun : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Halmstad : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Huddinge : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Jonkoping : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Karlstad : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Linkoeping : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Lulea : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Lund : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Malmoe : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Oerebro : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Stockholm : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Sundsvall : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Umea : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Uppsala : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Västerås : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Vaxjo : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Visby : Research Site:

A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma